#BEGIN_DRUGCARD DB04016

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C40H35N2O6P

# Chemical_IUPAC_Name:
[(1R)-2-{3-[methyl({1-[(naphthalen-2-yl)carbonyl]piperidin-4-yl})carbamoyl]naphthalen-2-yl}-1-(naphthalen-1-yl)-2-oxoethyl]phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid

# HET_ID:
OHH

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C40H35N2O6P/c1-41(32-19-21-42(22-20-32)39(44)31-18-17-26-9-2-3-11-28(26)23-31)40(45)36-25-30-13-5-4-12-29(30)24-35(36)37(43)38(49(46,47)48)34-16-8-14-27-10-6-7-15-33(27)34/h2-18,23-25,32,38H,19-22H2,1H3,(H2,46,47,48)/t38-/m1/s1

# InChI_Key:
InChIKey=XUJQPDQURBZEGJ-KXQOOQHDSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4016

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
670.6895

# Molecular_Weight_Mono:
670.223273374

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1T32

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
4.49

# Predicted_LogS:
-6.7

# Predicted_Water_Solubility:
1.33e-04 g/l

# Primary_Accession_No:
DB04016

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
656932

# PubChem_Substance_ID:
46507882

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT02424

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CN(C1CCN(CC1)C(=O)C1=CC2=CC=CC=C2C=C1)C(=O)C1=CC2=CC=CC=C2C=C1C(=O)[C@@H](C1=CC=CC2=CC=CC=C12)P(O)(O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:22:51 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CTSG

# Drug_Target_1_GenBank_ID_Gene:
M16117

# Drug_Target_1_GenBank_ID_Protein:
181182

# Drug_Target_1_GeneCard_ID:
CTSG

# Drug_Target_1_Gene_Name:
CTSG

# Drug_Target_1_Gene_Sequence:
>768 bp
ATGCAGCCACTCCTGCTTCTGCTGGCCTTTCTCCTACCCACTGGGGCTGAGGCAGGGGAG
ATCATCGGAGGCCGGGAGAGCAGGCCCCACTCCCGCCCCTACATGGCGTATCTTCAGATC
CAGAGTCCAGCAGGTCAGAGCAGATGTGGAGGGTTCCTGGTGCGAGAAGACTTTGTGCTG
ACAGCAGCTCATTGCTGGGGAAGCAATATAAATGTCACCCTGGGCGCCCACAATATCCAG
AGACGGGAAAACACCCAGCAACACATCACTGCGCGCAGAGCCATCCGCCACCCTCAATAT
AATCAGCGGACCATCCAGAATGACATCATGTTATTGCAGCTGAGCAGAAGAGTCAGACGG
AATCGAAACGTGAACCCAGTGGCTCTGCCTAGAGCCCAGGAGGGACTGAGACCCGGGACG
CTGTGCACTGTGGCCGGCTGGGGCAGGGTCAGCATGAGGAGGGGAACAGATACACTCCGA
GAGGTGCAGCTGAGAGTGCAGAGGGATAGGCAGTGCCTCCGCATCTTCGGTTCCTACGAC
CCCCGAAGGCAGATTTGTGTGGGGGACCGGCGGGAACGGAAGGCTGCCTTCAAGGGGGAT
TCCGGAGGCCCCCTGCTGTGTAACAATGTGGCCCACGGCATCGTCTCCTATGGAAAGTCG
TCAGGGGTTCCTCCAGAAGTCTTCACCAGGGTCTCAAGTTTCCTGCCCTGGATAAGGACA
ACAATGAGAAGCTTCAAACTGCTGGATCAGATGGAGACCCCCCTGTGA

# Drug_Target_1_General_Function:
Involved in immune response activity and protease activity

# Drug_Target_1_General_References:
2501794	Gabay JE, Scott RW, Campanelli D, Griffith J, Wilde C, Marra MN, Seeger M, Nathan CF: Antibiotic proteins of human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5610-4.
2569462	Hohn PA, Popescu NC, Hanson RD, Salvesen G, Ley TJ: Genomic organization and chromosomal localization of the human cathepsin G gene. J Biol Chem. 1989 Aug 15;264(23):13412-9.
3304423	Salvesen G, Farley D, Shuman J, Przybyla A, Reilly C, Travis J: Molecular cloning of human cathepsin G: structural similarity to mast cell and cytotoxic T lymphocyte proteinases. Biochemistry. 1987 Apr 21;26(8):2289-93.
3799965	Heck LW, Rostand KS, Hunter FA, Bhown A: Isolation, characterization, and amino-terminal amino acid sequence analysis of human neutrophil cathepsin G from normal donors. Anal Biochem. 1986 Oct;158(1):217-27.
8454293	Ludecke B, Poller W, Olek K, Bartholome K: Sequence variant of the human cathepsin G gene. Hum Genet. 1993 Mar;91(1):83-4.
8896442	Hof P, Mayr I, Huber R, Korzus E, Potempa J, Travis J, Powers JC, Bode W: The 1.8 A crystal structure of human cathepsin G in complex with Suc-Val-Pro-PheP-(OPh)2: a Janus-faced proteinase with two opposite specificities. EMBO J. 1996 Oct 15;15(20):5481-91.

# Drug_Target_1_HGNC_ID:
HGNC:2532

# Drug_Target_1_HPRD_ID:
00289

# Drug_Target_1_ID:
1514

# Drug_Target_1_Locus:
14q11.2

# Drug_Target_1_Molecular_Weight:
28838

# Drug_Target_1_Name:
Cathepsin G

# Drug_Target_1_Number_of_Residues:
255

# Drug_Target_1_PDB_ID:
1KYN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_1_Protein_Sequence:
>Cathepsin G precursor
MQPLLLLLAFLLPTGAEAGEIIGGRESRPHSRPYMAYLQIQSPAGQSRCGGFLVREDFVL
TAAHCWGSNINVTLGAHNIQRRENTQQHITARRAIRHPQYNQRTIQNDIMLLQLSRRVRR
NRNVNPVALPRAQEGLRPGTLCTVAGWGRVSMRRGTDTLREVQLRVQRDRQCLRIFGSYD
PRRQICVGDRRERKAAFKGDSGGPLLCNNVAHGIVSYGKSSGVPPEVFTRVSSFLPWIRT
TMRSFKLLDQMETPL

# Drug_Target_1_Reaction:
Specificity similar to chymotrypsin C

# Drug_Target_1_Signals:
1-18

# Drug_Target_1_Specific_Function:
Specificity similar to chymotrypsin C

# Drug_Target_1_SwissProt_ID:
P08311

# Drug_Target_1_SwissProt_Name:
CATG_HUMAN

# Drug_Target_1_Synonyms:
CG
Cathepsin G precursor
EC 3.4.21.20

# Drug_Target_1_Theoretical_pI:
11.69

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted protein. Cytoplasmic granule. Note=Mast cell granules

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CMA1

# Drug_Target_2_GenBank_ID_Gene:
M64269

# Drug_Target_2_GenBank_ID_Protein:
180542

# Drug_Target_2_GeneCard_ID:
CMA1

# Drug_Target_2_Gene_Name:
CMA1

# Drug_Target_2_Gene_Sequence:
>744 bp
ATGCTGCTTCTTCCTCTCCCCCTGCTGCTCTTTCTCTTGTGCTCCAGAGCTGAAGCTGGG
GAGATCATCGGGGGCACAGAATGCAAGCCACATTCCCGCCCCTACATGGCCTACCTGGAA
ATTGTAACTTCCAACGGTCCCTCAAAATTTTGTGGTGGTTTCCTTATAAGACGGAACTTT
GTGCTGACGGCTGCTCATTGTGCAGGAAGGTCTATAACAGTCACCCTTGGAGCCCATAAC
ATAACAGAGGAAGAAGACACATGGCAGAAGCTTGAGGTTATAAAGCAATTCCGTCATCCA
AAATATAACACTTCTACTCTTCACCACGATATCATGTTACTAAAGTTGAAGGAGAAAGCC
AGCCTGACCCTGGCTGTGGGGACACTCCCCTTCCCATCACAATTCAACTTTGTCCCACCT
GGGAGAATGTGCCGGGTGGCTGGCTGGGGAAGAACAGGTGTGTTGAAGCCGGGCTCAGAC
ACTCTGCAAGAGGTGAAGCTGAGACTCATGGATCCCCAGGCCTGCAGCCACTTCAGAGAC
TTTGACCACAATCTTCAGCTGTGTGTGGGCAATCCCAGGAAGACAAAATCTGCATTTAAG
GGAGACTCTGGGGGCCCTCTTCTGTGTGCTGGGGTGGCCCAGGGCATCGTATCCTATGGA
CGGTCGGATGCAAAGCCCCCTGCTGTCTTCACCCGAATCTCCCATTACCGGCCCTGGATC
AACCAGATCCTGCAGGCAAATTAA

# Drug_Target_2_General_Function:
Involved in protease activity

# Drug_Target_2_General_References:
1894611	Urata H, Kinoshita A, Perez DM, Misono KS, Bumpus FM, Graham RM, Husain A: Cloning of the gene and cDNA for human heart chymase. J Biol Chem. 1991 Sep 15;266(26):17173-9.
2049082	Jenne DE, Tschopp J: Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem J. 1991 Jun 1;276 ( Pt 2):567-8.
2071582	Caughey GH, Zerweck EH, Vanderslice P: Structure, chromosomal assignment, and deduced amino acid sequence of a human gene for mast cell chymase. J Biol Chem. 1991 Jul 15;266(20):12956-63.
8495723	Sukenaga Y, Kido H, Neki A, Enomoto M, Ishida K, Takagi K, Katunuma N: Purification and molecular cloning of chymase from human tonsils. FEBS Lett. 1993 May 24;323(1-2):119-22.
9400368	McGrath ME, Mirzadegan T, Schmidt BF: Crystal structure of phenylmethanesulfonyl fluoride-treated human chymase at 1.9 A. Biochemistry. 1997 Nov 25;36(47):14318-24.
9931257	Pereira PJ, Wang ZM, Rubin H, Huber R, Bode W, Schechter NM, Strobl S: The 2.2 A crystal structure of human chymase in complex with succinyl-Ala-Ala-Pro-Phe-chloromethylketone: structural explanation for its dipeptidyl carboxypeptidase specificity. J Mol Biol. 1999 Feb 12;286(1):163-73.

# Drug_Target_2_HGNC_ID:
HGNC:2097

# Drug_Target_2_HPRD_ID:
00346

# Drug_Target_2_ID:
1615

# Drug_Target_2_Locus:
14q11.2

# Drug_Target_2_Molecular_Weight:
27325

# Drug_Target_2_Name:
Chymase

# Drug_Target_2_Number_of_Residues:
247

# Drug_Target_2_PDB_ID:
1NN6

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_2_Protein_Sequence:
>Chymase precursor
MLLLPLPLLLFLLCSRAEAGEIIGGTECKPHSRPYMAYLEIVTSNGPSKFCGGFLIRRNF
VLTAAHCAGRSITVTLGAHNITEEEDTWQKLEVIKQFRHPKYNTSTLHHDIMLLKLKEKA
SLTLAVGTLPFPSQFNFVPPGRMCRVAGWGRTGVLKPGSDTLQEVKLRLMDPQACSHFRD
FDHNLQLCVGNPRKTKSAFKGDSGGPLLCAGVAQGIVSYGRSDAKPPAVFTRISHYRPWI
NQILQAN

# Drug_Target_2_Reaction:
Preferential cleavage: Phe! > Tyr! > Trp! > Leu!

# Drug_Target_2_Signals:
1-19

# Drug_Target_2_Specific_Function:
Major secreted protease of mast cells with suspected roles in vasoactive peptide generation, extracellular matrix degradation, and regulation of gland secretion

# Drug_Target_2_SwissProt_ID:
P23946

# Drug_Target_2_SwissProt_Name:
CMA1_HUMAN

# Drug_Target_2_Synonyms:
Chymase precursor
EC 3.4.21.39
Mast cell protease I

# Drug_Target_2_Theoretical_pI:
9.71

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB04016
